Lung Cancer

Filters

Online Exclusive

SALE UP TO 25% OFF

Shop The Sale

Regorafenib (LuciRegor) 40mg*28's | Lucius Laos Generic | GLT

LuciRegor — Lucius Pharmaceuticals regorafenib 40mg 28 tablets for mCRC, GIST & HCC.

Lazertinib (Lazcluze) 80/240mg | Janssen US Originator | GLT

Janssen Biotech originator Lazcluze (lazertinib) 80mg & 240mg tablets, third-generation EGFR-TKI for EGFR-mutated NSCLC, US-sourced.

Lazertinib (Leclaza) 80mg | Yuhan Korea Originator | GLT

Yuhan originator Leclaza (lazertinib) 80mg x 84 tablets, the first Korean-developed third-generation EGFR-TKI for NSCLC.

Lazertinib (LuciLazer) 80mg | Lucius Laos Generic | GLT

LuciLazer (lazertinib) 80mg x 60 tablets by Lucius Pharmaceuticals Laos, cost-effective generic third-generation EGFR-TKI.

Pembrolizumab (Keytruda) 100mg/4mL | Japan PMDA-Approved PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — Japan-sourced, PMDA-approved Keytruda at competitive global pricing

Pembrolizumab (Keytruda) 100mg/4mL & 50mg | US FDA-Approved PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — US-sourced, FDA-approved Keytruda at competitive global pricing

Pembrolizumab (Keytruda) 100mg/4mL | Hong Kong Registered PD-1 Inhibitor | GLT

PD-1 inhibitor for multiple cancers — Hong Kong-registered Keytruda at competitive global pricing

Pemomab (Pembrolizumab) 100mg/4mL | Affordable PD-1 Inhibitor Biosimilar | GLT

PD-1 inhibitor biosimilar for multiple cancers — cost-effective pembrolizumab at accessible pricing

Kadcyla Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Roche Switzerland Originator | GLT

Roche originator Kadcyla ado-trastuzumab emtansine (T-DM1) 100mg & 160mg vials, HER2-targeted ADC for HER2-positive breast...

UJVIRA Ado-trastuzumab Emtansine (T-DM1) 100/160mg | Zydus India Biosimilar | GLT

Zydus UJVIRA ado-trastuzumab emtansine (T-DM1) biosimilar 100mg & 160mg vials, world's first T-DM1 biosimilar ADC...

Ibtrozi (Taletrectinib) 200mg Capsules | ROS1 Inhibitor | GLT

Nuvation Bio next-generation ROS1 inhibitor for ROS1-positive NSCLC
售罄

塞尔帕替尼(Retevmo/睿妥)80mg — RET 驱动癌症 | 中国来源 | GLT

NMPA 批准的 RET 抑制剂,用于 RET 融合阳性非小细胞肺癌和甲状腺癌(中国)
售罄

Ceritinib(Spexib)150mg*150粒 | 诺华印度原研 | GLT

诺华印度市场的塞瑞替尼(Spexib)150mg 胶囊,每多包装 150 粒,用于 ALK 阳性非小细胞肺癌——与全球销售的 Zykadia 为同一原研药。
售罄

Tagrisso(奥希替尼)80mg*30 | 英国阿斯利康制药原研 | GLT

英国阿斯利康原研奥希替尼 80mg——用于非小细胞肺癌的参比 EGFR TKI
售罄

Tagrisso(奥希替尼)80mg×30 | 阿斯利康 中国 NMPA | GLT

中国大陆 Tagrisso 80mg — NMPA 批准、纳入国家医保的原研奥希替尼
售罄

Ceritinib (Zykadia) 150mg*10's | Novartis Switzerland Originator | GLT

Novartis Switzerland originator Zykadia (ceritinib) 150mg capsules, 10-capsule starter pack for ALK-positive NSCLC.
售罄

塞瑞替尼(赞可达)150mg*150粒 | 诺华 中国来源 | GLT

诺华中国来源的赞可达(塞瑞替尼)150mg 胶囊,已获 NMPA 批准并纳入医保,用于 ALK 阳性非小细胞肺癌。
售罄

Ceritinib (Noxalk) 150mg*90's | Natco India Generic | GLT

Noxalk — Natco Pharma India generic ceritinib 150mg, 90-capsule pack for ALK-positive NSCLC.
售罄

Tepmetko (Tepotinib) 225mg*60 | Merck KGaA Germany Originator | GLT

Merck KGaA Germany originator tepotinib 225mg — the first oral MET inhibitor for NSCLC
售罄

拓得康(特泊替尼)225mg*60 | 默克 中国 NMPA | GLT

中国大陆拓得康 225mg——获 NMPA 批准、纳入国家医保的原研特泊替尼。
排序
  • 推荐
  • 价格由低到高
  • 价格由高到底
  • 最新
  • 销量最高